 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that RGNX's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

REGENXBIO (RGNX, $21.06) Stochastic Oscillator left the oversold zone on March 28, 2024

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Regenxbio's ABBV-RGX-314 featured in published study for wet AMD

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating...

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days PR Newswire ROCKVILLE, Md...

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

REGENXBIO (RGNX, $21.59) Stochastic Oscillator left the oversold zone on March 25, 2024

REGENXBIO (RGNX, $22.35) Stochastic Oscillator left the oversold zone on March 18, 2024

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

This is a Bearish indicator signaling RGNX's price could decline from here. Traders may explore shorting the stock or put options...

REGENXBIO (RGNX, $21.85) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 14, 2024

REGENXBIO to Participate in Upcoming Investor Conferences REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire ROCKVILLE, Md., March 11, 2024 ROCKVILLE, Md., March 11, 2024...

REGENXBIO to Participate in Upcoming Investor Conferences

RBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Volume (M)	560,518.00
52-Wk High	$28.80
52-Wk Low	$11.83

RGNX Regenxbio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals